Author Correction: BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer

Niki Karachaliou; Jordi Codony-Servat; Cristina Teixidó; Sara Pilotto; Ana Drozdowskyj; Carles Codony-Servat; Ana Giménez-Capitán; Miguel Angel Molina-Vila; Jordi Bertrán-Alamillo; Radj Gervais; Bartomeu Massuti; Teresa Morán; Margarita Majem; Enriqueta Felip; Enric Carcereny; Rosario García-Campelo; Santiago Viteri; María González-Cao; Daniela Morales-Espinosa; Alberto Verlicchi; Elisabetta Crisetti; Imane Chaib; Mariacarmela Santarpia; José Luis Ramírez; Joaquim Bosch-Barrera; Andrés Felipe Cardona; Filippo de Marinis; Guillermo López-Vivanco; José Miguel Sánchez; Alain Vergnenegre; José Javier Sánchez Hernández; Isabella Sperduti; Emilio Bria; Rafael Rosell

doi:10.1038/s41598-023-30374-9

Author Correction: BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer

Sci Rep. 2023 Mar 3;13(1):3620. doi: 10.1038/s41598-023-30374-9.

Authors

Niki Karachaliou¹, Jordi Codony-Servat², Cristina Teixidó², Sara Pilotto³, Ana Drozdowskyj⁴, Carles Codony-Servat², Ana Giménez-Capitán², Miguel Angel Molina-Vila², Jordi Bertrán-Alamillo², Radj Gervais⁵, Bartomeu Massuti⁶, Teresa Morán⁷, Margarita Majem⁸, Enriqueta Felip⁹, Enric Carcereny⁷, Rosario García-Campelo¹⁰, Santiago Viteri¹, María González-Cao¹, Daniela Morales-Espinosa¹, Alberto Verlicchi¹¹, Elisabetta Crisetti¹², Imane Chaib⁷, Mariacarmela Santarpia¹³, José Luis Ramírez⁷, Joaquim Bosch-Barrera¹⁴, Andrés Felipe Cardona¹⁵, Filippo de Marinis¹⁶, Guillermo López-Vivanco¹⁷, José Miguel Sánchez¹⁸, Alain Vergnenegre¹⁹, José Javier Sánchez Hernández²⁰, Isabella Sperduti²¹, Emilio Bria³, Rafael Rosell^{22

23

24

25

26}

Affiliations

¹ Instituto Oncológico Dr Rosell, Quiron-Dexeus University Hospital, Barcelona, Spain.
² Pangaea Biotech, Barcelona, Spain.
³ Department of Medical Oncology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
⁴ Pivotal, Madrid, Spain.
⁵ Centre François Baclesse, Caen, France.
⁶ Hospital General de Alicante, Alicante, Spain.
⁷ Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain.
⁸ Hospital de Sant Pau, Barcelona, Spain.
⁹ Hospital Vall d'Hebron, Barcelona, Spain.
¹⁰ Complexo Hospitalario Universitario La Coruña, La Coruña, Spain.
¹¹ Ospedale Santa Maria delle Croci, Ravenna, Italy.
¹² Department of Medical and Surgical Sciences, Institute of Respiratory Diseases, University of Foggia, Foggia, Italy.
¹³ Human Pathology Department, Medical Oncology Unit, University of Messina, Messina, Italy.
¹⁴ Catalan Institute of Oncology, Hospital Josep Trueta, Girona, Spain.
¹⁵ Clinical and Traslational Oncology Group, Institute of Oncology, Clínica del Country, Bogotá, Colombia.
¹⁶ Divisione di Oncologica Toracica, Direttore, Istituto Europeo di Oncologia-IEO, Milano, Italy.
¹⁷ Chief, Medical Oncology Service, Hospital de Cruces, Barakaldo, Vizcaya, Spain.
¹⁸ Medical Oncology Service, Hospital de la Princesa, Madrid, Spain.
¹⁹ Hôpital du Cluzeau, Limoges, France.
²⁰ Unidad de Investigación en Salud Pública CIDICS-UANL, Monterrey, Mexico.
²¹ Biostatistics, Regina Elena National Cancer Institute, Rome, Italy.
²² Instituto Oncológico Dr Rosell, Quiron-Dexeus University Hospital, Barcelona, Spain. [email protected].
²³ Pangaea Biotech, Barcelona, Spain. [email protected].
²⁴ Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain. [email protected].
²⁵ Molecular Oncology Research (MORe) Foundation, Barcelona, Spain. [email protected].
²⁶ Germans Trias i Pujol Health Sciences Institute and Hospital, Campus Can Ruti, Barcelona, Spain. [email protected].

No abstract available

Publication types

Published Erratum